Safety-relevant label changes don't wait for a convenient review cycle. A new adverse event, a revised contraindication, or an added boxed warning can appear on a competitor or reference label at any time, and the gap between when it happens and when your team notices is where risk lives. Manual monitoring processes were never built to close that gap fast enough. Dr. Evidence's pharmacovigilance solutions replace periodic manual checks with continuous, automated safety intelligence, so your team is never the last to know about a change that matters.
Pharmacovigilance and drug safety teams use Dr. Evidence for ongoing signal monitoring and label surveillance across their own products and the broader competitive landscape. Regulatory affairs teams rely on the same intelligence to stay ahead of safety-driven label updates and prepare the health authority submissions that follow. And compliance teams depend on the platform's traceable, source-cited data to maintain audit readiness, so every safety decision has a clear evidentiary trail behind it.
Dr. Evidence monitors competitor and reference-listed drug (RLD) labels for the changes that matter most: new adverse events, added or revised contraindications, dosing changes, and boxed warning updates. Automated alerts mean your team responds to safety-relevant changes when they happen, not weeks later during a routine review.
Comparing adverse events across labels has traditionally meant manual, line-by-line review — slow, error-prone, and difficult to scale across a full portfolio. Dr. Evidence's AI-powered comparison view changes that, generating a detailed adverse event comparison across label versions instantly, with a summarized view of key differences and precise identification of true indications that eliminates the noise of unrelated contraindications. This is Human-in-Command AI in practice: the platform surfaces the comparison, and your safety team makes the call, fully informed and without wading through pages of redundant text.
In pharmacovigilance, an answer is only as good as its source — and general AI tools that generate plausible-sounding but unverified information aren't just unhelpful in this context; they're a liability. Dr.Evidence is built exclusively on data approved by health authorities, curated specifically for safety and regulatory use. Every answer is traceable to a real, verified source, which means no hallucinated adverse events and no fabricated precedent entering your safety record. Your proprietary data stays yours.
And because the platform is Human-in-Command by design, every AI-assisted comparison remains fully auditable. Your team retains the judgment; the platform provides the defensible evidence behind it. That combination of automation and defensibility is what turns pharmacovigilance automation from a convenience into a genuine safety-regulatory intelligence foundation your compliance team can stand behind.
The difference between a pharmacovigilance team that's always scrambling and one that's always prepared usually comes down to one thing: how quickly they learn about a change. Without automated monitoring, safety teams discover critical label changes after the fact, often during an unrelated review, or worse, after a regulator or partner raises the question first.
With Dr. Evidence, that dynamic reverses. Your team knows when a relevant label changes, evaluates it on its own timeline, and walks into every regulatory or compliance conversation already prepared, rather than catching up in real time.
Clinical safety regulatory intelligence shouldn't depend on catching every change manually — it should be built into the way your team works every day.
Book a Demo to see Dr. Evidence's pharma labeling software in action to see exactly how it works.